Calphron Pregnancy Warnings
This drug should be used only if clearly needed.
US FDA pregnancy category: C
Comments:
-Treatment may lead to hypercalcemia.
-Hypercalcemia risk increases with concomitant calcium and vitamin D use.
-Maintaining normal serum calcium is important for maternal and fetal well-being.
-Maternal hypercalcemia increases the risk for stillbirth, preterm birth, and neonatal hypocalcemia and hypoparathyroidism.
-Maternal calcium acetate use is not expected to harm a fetus, provided maternal serum calcium levels are appropriately monitored.
Animal studies have not been conducted. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
See references
